Tests BPI-572270 in adults with advanced solid tumors carrying RAS mutations
Tests BPI-572270 in adults with advanced cancers carrying certain RAS mutations.
Plain-language title generated from the registry record
Registry title: Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Key facts
- Where
- Bedford Park, Blacktown, Heidelberg, Nedlands, Randwick, and Sydney, AustraliaSee the 6 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an advanced solid tumor that has a RAS gene mutation and who have already had standard treatment.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Advanced solid tumor, confirmed under the microscope. The trial lists lung cancer (NSCLC), colorectal cancer and pancreatic cancer (PDAC).
- Earlier treatment
- People must have had the standard treatment that fits their tumor type and stage.
- Biomarker or test result
- A RAS gene mutation found by DNA sequencing.
Main reasons for not taking part
- Primary tumor of the brain or spinal cord (central nervous system)
- Active brain metastases that have not been treated
- Stomach or bowel problems that make it hard to swallow or absorb a pill
- Another unstable or serious medical condition, in the investigator's opinion
Read by machine on 9 November 2026.
Where in Australia
- Southern Oncology Clinical Research Unit (SOCRU)Bedford Park, AustraliaNot yet recruiting
- Blacktown HospitalBlacktown, AustraliaNot yet recruiting
- Warringal Private HospitalHeidelberg, AustraliaNot yet recruiting
- Linear Clinical Research LtdNedlands, AustraliaNot yet recruiting
- Scientia Clinical ResearchRandwick, AustraliaNot yet recruiting
- GenesisCare St Leonards, 7 Westbourne St, St LeonardsSydney, AustraliaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Betta Pharmaceuticals Co., Ltd.
- Trial code
- NCT07435038
- Record updated
- 18 September 2026
- Original description
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.Read full original descriptionShow less
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS.
Evaluate the safety and tolerability of BPI-572270 in adult patients with specific RAS mutant advanced solid tumors.
Inclusion: Histologically confirmed advanced solid tumor with RAS mutations identified through deoxyribonucleic acid (DNA) sequencing; Have received prior standard therapy appropriate for tumor type and stage; Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate organ function.
Exclusion: History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy; Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication; Primary central nervous system (CNS) tumors active and untreated brain metastases.